|
Jul 1
|
Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 | Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth
|
|
Jun 30
|
Gilead extends gains after Supreme Court upheld an Obamacare provision
|
|
Jun 30
|
This firm represents one of investing’s toughest moral debates
|
|
Jun 28
|
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
|
|
Jun 27
|
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
|
|
Jun 27
|
Gilead, Exact Jump After The Supreme Court Upholds A 'Cornerstone' Of Health Care
|
|
Jun 27
|
Kymera’s partnerships with Sanofi and Gilead drive value
|
|
Jun 27
|
Debut Named to TIME's List of the TIME100 Most Influential Companies 2025
|
|
Jun 26
|
Northwell Health named to TIME100 Most Influential Companies 2025 list
|
|
Jun 26
|
Kymera weakness a buying opportunity, says Stifel
|
|
Jun 26
|
Morning Movers: General Mills dips following fourth quarter report
|
|
Jun 26
|
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
|
|
Jun 25
|
Gilead Sciences (GILD) Stock Moves -1.18%: What You Should Know
|
|
Jun 2
|
Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study
|
|
Jun 1
|
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
|
|
May 31
|
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
|
|
May 31
|
Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
|
|
May 30
|
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
|
|
May 30
|
Gilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden
|
|
May 29
|
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
|